Progenics Pharma (PGNX) Tops Q1 EPS by 1c

Progenics Pharma (NASDAQ: PGNX) reported Q1 EPS of ($0.15), $0.01 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $200 thousand versus the consensus estimate of $1.3 million.

For earnings history and earnings-related data on Progenics Pharma (PGNX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c